Abstract
Late-onset asthma is common, associated with poor outcome, underdiagnosed and undertreated, possibly due to the modifying effect of ageing on disease expression. Although the diagnostic work-up in elderly individuals suspected of having asthma follows the same steps as in younger individuals (case history and spirometry), it is important to acknowledge that elderly individuals are likely to have diminished bronchodilator reversibility and some degree of fixed airflow obstruction. Elderly individuals, therefore, often require further objective tests, including bronchial challenge testing, to objectively confirm asthma. If necessary, a trial of oral or inhaled corticosteroid might be necessary. Asthma can be diagnosed when increased airflow variability is identified in a symptomatic patient, and if the patient does not have a history of exposure, primarily smoking, known to cause chronic obstructive pulmonary disease, the diagnosis is asthma even if the patient does not have fully reversible airflow obstruction. Pharmacological therapy in patients with late-onset asthma follows international guidelines, including treatment with the lowest effective dose of inhaled corticosteroid to minimize the risk of systemic effects. However, most recommendations are based on extrapolation from findings in younger patients. Comorbidities are very common in patients with late-onset asthma and need to be taken into account in the management of the disease. In conclusion, late-onset asthma is poorly recognized and sub-optimally treated, the latter not least because elderly patients are excluded from most randomized controlled trials. Future studies should focus on the development of evidence-based guidelines for diagnosis and the pharmacological therapy of asthma in the elderly, including late-onset asthma.
Similar content being viewed by others
References
Basagana X, Sunyer J, Kogevinas M, Zock JP, Duran-Tauleria E, Jarvis D, et al. Socioeconomic status and asthma prevalence in young adults: the European Community Respiratory Health Survey. Am J Epidemiol. 2004;160:178–88.
Enright PL, McClelland RL, Newman AB, Gottlieb DJ, Lebowitz MD. Underdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research Group. Chest. 1999;116:603–13.
Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–39.
Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–43.
Porsbjerg C, Lange P, Ulrik CS. Lung function impairment increases with age of diagnosis in adult onset asthma. Respir Med. 2015;109:821–7.
Parameswaran K, Hildreth AJ, Chadha D, Keaney NP, Taylor IK, Bansal SK. Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. Respir Med. 1998;92:573–7.
De Marco R, Locatelli F, Cerveri I, Bugiani M, Marinoni A, Giammanco G. Incidence and remission of asthma: a retrospective study on the natural history of asthma in Italy. J Allergy Clin Immunol. 2002;110:228–35.
Herscher ML, Wisnivesky JP, Busse PJ, Hanania NA, Sheng T, Wolf MS, et al. Characteristics and outcomes of older adults with long-standing versus late-onset asthma. J Asthma 2016;1–7. doi:10.1080/02770903.2016.1211141.
Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med. 2005;99:11–9.
Scichilone N, Pedone C, Battaglia S, Sorino C, Bellia V. Diagnosis and management of asthma in the elderly. Eur J Intern Med. 2014;25:336–42.
Gershon AS, Victor JC, Guan J, Aaron SD, To T. Pulmonary function testing in the diagnosis of asthma: a population study. Chest. 2012;141:1190–6.
Sorino C, Battaglia S, Scichilone N, Pedone C, Antonelli-Incalzi R, Sherrill D, et al. Diagnosis of airway obstruction in the elderly: contribution of the SARA study. Int J Chron Obstruct Pulm Dis. 2012;7:389–95.
Haynes JM. Pulmonary function test quality in the elderly: a comparison with younger adults. Respir Care. 2014;59:16–21.
Bellia V, Pistelli R, Catalano F, Antonelli-Incalzi R, Grassi V, Melillo G, et al. Quality control of spirometry in the elderly. The SA.R.A. study. SAlute Respiration nell’Anziano = Respiratory Health in the Elderly. Am J Respir Crit Care Med. 2000;161:1094–100.
Bellia V, Sorino C, Catalano F, Augugliaro G, Scichilone N, Pistelli R, et al. Validation of FEV6 in the elderly: correlates of performance and repeatability. Thorax. 2008;63:60–6.
Pedone C, Bellia V, Sorino C, Forastiere F, Pistelli R, Antonelli-Incalzi R. Prognostic significance of surrogate measures for forced vital capacity in an elderly population. J Am Med Dir Assoc. 2010;11:598–604.
Battaglia S, Benfante A, Spatafora M, Scichilone N. Asthma in the elderly: a different disease? Breathe (Sheff). 2016;12:18–28.
Godinho Netto AC, Dos Reis TG, Matheus CF, Aarestrup BJ, Aarestrup FM. Fraction of exhaled nitric oxide measurements in the diagnoses of asthma in elderly patients. Clin Interv Aging. 2016;11:623–9.
Columbo M, Wong B, Panettieri RA Jr, Rohr AS. Asthma in the elderly: the role of exhaled nitric oxide measurements. Respir Med. 2013;107:785–7.
Kawamatawong T, Siripongpun S, Rerkpattanapipat T. Role of eosinophilic inflammation and atopy in elderly asthmatic patients. Asia Pac Allergy. 2016;6:181–6.
Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–24.
Backer V, Sverrild A, Ulrik CS, Bodtger U, Seersholm N, Porsbjerg C. Diagnostic work-up in patients with possible asthma referred to a university hospital. Eur Clin Respir J 2015,2. doi:10.3402/ecrj.v2.27768.
Ulrik CS, Lange P. Cigarette smoking and asthma. Monaldi Arch Chest Dis. 2001;56:349–53.
de Marco R, Cappa V, Accordini S, Rava M, Antonicelli L, Bortolami O, et al. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. Eur Respir J. 2012;39:883–92.
Celli BR, Tashkin DP, Rennard SI, McElhattan J, Martin UJ. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respir Med. 2011;105:1176–88.
Kjeldgaard P DR, Løkke A, Ulrik CS. Detection of COPD in a high-risk population: should the diagnostic work-up include bronchodilator testing? Int J COPD 2015;10:407–14.
Asthma, COPD and the asthma-COPD overlap syndrome (ACOS). 2014.
Global Initiative for Asthma (GINA). 2015. http://www.ginasthma.org. Accessed 26 Oct 2016.
Shaker SB, Dirksen A, Ulrik CS, Hestad M, Stavngaard T, Laursen LC, et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD. 2009;6:104–11.
Sekine Y, Fujisawa T, Suzuki K, Tsutatani S, Kubota K, Ikegami H, et al. Detection of chronic obstructive pulmonary disease in community-based annual lung cancer screening: Chiba Chronic Obstructive Pulmonary Disease Lung Cancer Screening Study Group. Respirology. 2014;19:98–104.
Turan O, Turan PA, Mirici A. Parameters affecting inhalation therapy adherence in elderly patients with chronic obstructive lung disease and asthma. Geriatr Gerontol Int 2016. doi:10.1111/ggi.12823.
Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75:18–25.
Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941–55.
Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD10115.
Stanford RH, Blanchette CM, Roberts MH, Petersen H, Fuhlbrigge AL. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population. Am J Geriatr Pharmacother. 2012;10:343–51.
Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.
Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67:751–3.
Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–207.
Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206.
Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369:1491–501.
Creticos P, Knobil K, Edwards LD, Rickard KA, Dorinsky P. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol. 2002;88:401–9.
Ye YM, Kim SH, Hur GY, Kim JH, Park JW, Shim JJ, et al. Addition of montelukast to low-dose inhaled corticosteroid leads to fewer exacerbations in older patients than medium-dose inhaled corticosteroid monotherapy. Allergy Asthma Immunol Res. 2015;7:440–8.
Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma. 2012;49:530–4.
Verma P, Randhawa I, Klaustermeyer WB. Clinical efficacy of omalizumab in an elderly veteran population with severe asthma. Allergy Asthma Proc. 2011;32:346–50.
Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105:313–9.
Maykut RJ, Kianifard F, Geba GP. Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. J Asthma. 2008;45:173–81.
Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–24.
Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–107.
Park HW, Kim TW, Song WJ, Kim SH, Park HK, Kim SH, et al. Prediction of asthma exacerbations in elderly adults: results of a 1-year prospective study. J Am Geriatr Soc. 2013;61:1631–2.
Bellia V, Pedone C, Catalano F, Zito A, Davi E, Palange S, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest. 2007;132:1175–82.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
CSU has no conflict of interest in relation to this manuscript.
Funding
No sources of funding were used to support the writing of this manuscript.
Rights and permissions
About this article
Cite this article
Ulrik, C.S. Late-Onset Asthma: A Diagnostic and Management Challenge. Drugs Aging 34, 157–162 (2017). https://doi.org/10.1007/s40266-017-0437-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-017-0437-y